This sounds very promising
2.1.9 D-2570 D-2570 is a novel oral TYK2 inhibitor being developed for autoimmune diseases including psoriasis and UC evaluated in a Phase 2 multicenter double-blind, placebo-controlled RCT (NCT07035041) with 120 participants randomized 1:1:1 to two different D-2570 dosing arms or placebo for 12 weeks
What was interesting about this study is that there seems to be more to the effect of these weight loss medications than just helping the patient lose weight
Options may include increasing your metformin dose (if not already at maximum), adding a sulfonylurea, SGLT2 inhibitor, or considering injectable therapies such as insulin or alternative GLP-1 receptor agonists if appropriate
Monitoring may include A1C, home glucose readings, kidney function, and eye health when clinically appropriate
Since Wegovy can change how quickly you feel alcohols effects, drinking less or more slowly becomes even more important